MedSpa Institute of America

Item 7 outlines an initial investment of $101,600 to $200,000, including a $45,000 franchise fee—mid-range for adult education franchises but hefty for a 2024 newcomer with only one corporate location. Ongoing fees hit 7% royalties plus 1% brand/ad fund, plus $350-$450 monthly software subscriptions, totaling around 8% plus fixed costs that could pressure thin margins in training. No Item 19 means zero disclosed revenue or profit figures, a major gap forcing reliance on FDD Item 19 alternatives like SBA data: 18 loans averaging $329,222 signal aggressive expansion, but the 11.1% default rate towers over typical SBA benchmarks (under 3%), flagging potential cash flow struggles or overleveraging in a competitive field against independents.

System health shows franchising since 2024 with FDD dated 2025, implying embryonic growth—no contraction yet, but scant unit data and single corporate HQ underscore execution risks. High loan volume suggests franchisor push for scale in high-demand aesthetics training (lasers, injections), yet defaults warn of unproven model viability. For investors, key factors tilt cautious: absence of financial transparency amplifies new-brand volatility; weigh medspa boom against 11% default signal before committing six figures.